
    
      Part 1: the total duration will be up to approximately 50 weeks (or 68 weeks in Japan). Part
      2: the total duration will be up to approximately 222 weeks that will consist of 8.5 weeks of
      screening period, 52 weeks of treatment period, 156 weeks of long term follow-up period and 8
      weeks of post-treatment period.

      At the end of a 52-week main placebo-controlled treatment period, all patients will be
      evaluated for possibility to transition to receive active treatment for 156 weeks plus 8 week
      post-treatment observation.
    
  